| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T131 |
0-16 |
Sentence |
denotes |
Tang et al [54]. |
| T132 |
17-98 |
Sentence |
denotes |
Open label, randomized controlled trial HCQ group: n = 70; control group: n = 80. |
| T133 |
99-305 |
Sentence |
denotes |
HCQ 1200 mg daily for 3 days, 800 mg daily for 2 weeks (mild to moderate disease)/3 weeks(severe disease) HCQ did not show additional benefits of vial elimination in patients with mild to moderate COVID-19. |
| T134 |
306-334 |
Sentence |
denotes |
Randomized controlled study. |
| T135 |
335-533 |
Sentence |
denotes |
Lack of a placebo control group; Design introduces the possibility of biased investigator determined assessment and unbalanced dosage adjustment; Randomization of sequential envelopes may be biased. |
| T136 |
534-717 |
Sentence |
denotes |
The antiviral efficacy of HCQ was not assessed at an earlier stage; Most patients are mild to severe, and the effect of HCQ on disease progression or regression could not be provided. |
| T137 |
718-794 |
Sentence |
denotes |
The trial terminated early due to the difficulty to recruit enough patients. |
| T138 |
795-1007 |
Sentence |
denotes |
Some secondary endpoints could not be analyzed by the cutoff date; Viral RNA specimens are mostly from the upper respiratory tract rather than bronchoalveolar lavage fluid, which may cause false negative results. |
